Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRISE: Adjuvant nivolumab vs S-1 vs surgery alone after neoadjuvant chemotherapy and esophagectomy in esophageal squamous cell carcinoma
jRCTs031230219Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of nivolumab and tegafur in Esophageal Squamous Cell Carcinoma (ESCC) (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Relapse-free survival. Started Sep 2023; status: recruiting.
02
Drugs
nivolumabtegafur
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCTs031230219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230219.